High plasma concentrations of paroxetine impede clinical response in patients with panic disorder

Therapeutic Drug Monitoring

Volumn 29, Issue 1, 2007, Pages 40-44

  Watanabe, Takashi ^a   Ueda, Mikito ^a   Saeki, Yoshinori ^a   Hirokane, Genta ^b   Morita, Sachiyo ^b   Okawa, Masako ^b   Akiyama, Kazufumi ^a   Shimoda, Kazutaka ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Panic and Agoraphobia Scale; Panic disorder; Paroxetine; Plasma concentrations; Therapeutic drug monitoring

Indexed keywords

PAROXETINE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DROWSINESS; DRUG BLOOD LEVEL; FEMALE; HUMAN; JAPANESE; MALE; MULTIPLE REGRESSION; PANIC; PRIORITY JOURNAL; RATING SCALE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; AZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LORAZEPAM; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS;

EID: 33847102615     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31802bb194     Document Type: Article

References (15)

1. Ueda M, Hirokane G, Morita S, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:486-491.
2. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60:553-557.
3. Normann C, Horn M, Hummel B, et al. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry. 2004;37:123-126.
4. Tasker TC, Kaye CM, Zussman BD, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl. 1989;350:152-155.
5. Gilles M, Deuschle M, Kellner S, et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry. 2005;38:118-121.
6. Härtter S, Wetzel H, Hammes E, et al. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry. 1998;31:199-200.
7. Sandmann J, Lorch B, Bandelow B, et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry. 1998;31:117-121.
8. Michelson D, Lydiard RB, Pollack MH, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998;155:1570-1577.
9. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995;10:73-81.
10. Snaith RP, Baugh SJ, Clayden AD, et al. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry. 1982;141:518-523.
11. Bandelow B, Brunner E, Broocks A, et al. The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res. 1998;77:43-49.
12. Hikida K, Inoue Y, Nouchi E, et al. Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography Jpn J Clin Chem. 1990;19:354-359.
13. Stahl SM. Essential Psychopharmacology. 2nd ed. New York: Cambridge University Press; 2000.
14. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry. 1993;54:435-438.
15. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry. 2002;63:854-855.